Publicaciones (67) Publicaciones de JULIAN CARRETERO ASUNCION

2024

  1. Deciphering fibroblast-induced drug resistance in non-small cell lung carcinoma through patient-derived organoids in agarose microwells

    Lab on a Chip

  2. La NNMT de los CAFS: Implicaciones en la resistencia terapéutica del adenocarcinoma pulmonar

    Pharmaceutical care España, Vol. 26, Núm. 2, pp. 328-328

  3. Molecular mechanisms of cancer cachexia. Role of exercise training

    Molecular Aspects of Medicine, Vol. 99

  4. miRNAs Related to Immune Checkpoint Inhibitor Response: A Systematic Review

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. La incorporación de nuevas tecnologías a los seminarios de Fisiopatología en el grado de Farmacia mejora la calidad del proceso de enseñanza aprendizaje

    In-Red 2023. IX Congreso Nacional de Innovación Educativa y Docencia en Red: Modelos transformadores docentes para un aprendizaje a lo largo de la vida

  2. The Role of Aryl Hydrocarbon Receptor in the Endothelium: A Systematic Review

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

2022

  1. A Very Rare Variant in SREBF2, a Possible Cause of Hypercholesterolemia and Increased Glycemic Levels

    Biomedicines, Vol. 10, Núm. 5

  2. Matrix Metalloproteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN/CD147 Comes into Play

    International Journal of Molecular Sciences, Vol. 23, Núm. 13

  3. New roles for AP-1/JUNB in cell cycle control and tumorigenic cell invasion via regulation of cyclin E1 and TGF-β2

    Genome Biology, Vol. 23, Núm. 1

2021

  1. Epigenetics and precision medicine in lung cancer

    Epigenetics in Precision Medicine (Elsevier), pp. 109-145

2020

  1. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro

    PLoS ONE, Vol. 15, Núm. 2

  2. Clinical significance of epithelial–mesenchymal transition-related markers expression in the micrometastatic sentinel lymph node of NSCLC

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 381-391

  3. Comprehensive analysis of SWI/SNF inactivation in lung adenocarcinoma cell models

    Cancers, Vol. 12, Núm. 12, pp. 1-14

  4. Endothelin-1-mediated drug resistance in EGFR-mutant non-small cell lung carcinoma

    Cancer Research, Vol. 80, Núm. 19, pp. 4224-4232

  5. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

    Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282

  6. Srebf2 locus overexpression reduces body weight, total cholesterol and glucose levels in mice fed with two different diets

    Nutrients, Vol. 12, Núm. 10, pp. 1-15

2019

  1. CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC

    Cancer Research, Vol. 79, Núm. 17, pp. 4439-4452

  2. LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics

    Analytical Chemistry, Vol. 91, Núm. 1, pp. 836-845

2018

  1. De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer

    FASEB Journal, Vol. 32, Núm. 12, pp. 7018-7027

  2. PanDrugs: A novel method to prioritize anticancer drug treatments according to individual genomic data

    Genome Medicine, Vol. 10, Núm. 1